Session » ACR Plenary Session II: Discovery 2015

Date: Monday, November 9, 2015

Time: 11:00AM-12:30PM

Meeting: 2015 ACR/ARHP Annual Meeting

Abstract Number: 1994

Electronic Patient Reported Outcome Measures in Systemic Lupus Erythematosus : A Potential Disease Modifying Impact on the Management of Disease Activity Flares and Damage Accrual

Abstract Number: 1995

Does the Risk of Serious Infections Among Elderly RA Patients Differ By Age of Disease Onset?

Abstract Number: 1996

Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies

Abstract Number: 1997

Underuse of Methotrexate (MTX) in the Treatment of Rheumatoid Arthritis (RA) in the United States (US): Results of a Comprehensive Pharmaceutical Claims Analysis

Abstract Number: 1998

A National Electronic Health Record-Enabled Registry in Rheumatology: The ACR’s Rheumatology Informatics System for Effectiveness (RISE)

Abstract Number: 1999

Improvement in Mortality in RA Compared to the General Population – Closing the Mortality Gap

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.